Our Technology

HaemaLogiX is committed to changing the outlook for multiple myeloma patients. The immunotherapies that we’re developing are uniquely designed to target cancerous plasma cells with exceptional precision. Importantly this enables them to spare normal plasma cells, delivering the potential to effectively treat myeloma, without impacting the patient’s immune response which is required to fight infection and the cancer itself. Our targeted approach has the potential to keep patients stronger and healthier during treatment - offering greater efficacy, yet reduced toxicity.

HaemaLogiX’s immunotherapies bind to unexploited and unique targets (antigens) on the surface of cancerous plasma cells. These antigens are called kappa myeloma antigen (KMA) and lambda myeloma antigen (LMA), and are absent on normal plasma cells . This may provide improved on-target efficacy, reduced off-tumour toxicity and preserve immune function, offering a key differentiation to current treatment. There are no competing immunotherapies for these targets in the market, providing a distinct competitive advantage.

Approximately 70% of myeloma patients are kappa-type and would express KMA and 30% are lambda-type and would express LMA on their myeloma plasma cells. Myeloma patients only express one or the other antigen on their myeloma plasma cells.